Clinical Research Directory

Inclusion Criteria: * Newly diagnosed, histologically confirmed invasive breast cancer that is triple negative (estrogen receptor \[ER\], progesterone receptor \[PR\], and HER2-neu negative) or HER2-positive (any ER/PR status) * Unresected, untreated breast cancer that is T2, T3, or T4a-c; any N (nodal status); and M0 (not metastatic) * ECOG Performance Status of 0 or 1 * Planning to receive a neoadjuvant chemotherapy regimen containing a taxane ± an anthracycline for at least 4 cycles. Patients with HER2-positive disease must also be planning to receive HER2-targeted therapy. * Diagnostic tumor material must be available for correlative analyses * Patients must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * No prior treatment for the current breast cancer, though prior use of selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs) for the prevention of breast cancer is acceptable. * Women who are pregnant or nursing are excluded. * No history of another primary malignancy in the last 5 years prior to registration. Patients with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.